Recent trends in antibiotic resistance in European ICUs

Current Opinion in Critical Care

Volumn 17, Issue 6, 2011, Pages 658-665

  Van Duijn, Pleun J ^a   Dautzenberg, Mirjam J D ^a   Oostdijk, Evelien A N ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antimicrobial resistance; Gram negative bacteria; ICU; methicillin resistant Staphylococcus aureus; multidrug resistance

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; ENZYME; EXTENDED SPECTRUM BETA LACTAMASE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; LINEZOLID; NEW DELHI METALLO BETA LACTAMASE ENZYME; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BODY BURDEN; DIAGNOSTIC TEST; DISEASE BURDEN; DRUG DOSE REGIMEN; DRUG SENSITIVITY; DRUG USE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EUROPE; GENOTYPE; GRAM POSITIVE BACTERIUM; HEALTH CARE COST; HEALTH CARE PLANNING; HOSPITAL HYGIENE; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PLASMID; REVIEW; VANCOMYCIN SUSCEPTIBILITY;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INFECTION CONTROL; INTENSIVE CARE UNITS; UNIVERSAL PRECAUTIONS; VANCOMYCIN RESISTANCE; WORLD HEALTH;

EID: 81155139530     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32834c9d87     Document Type: Review

References (82)

1. Bonten MJ. Healthcare epidemiology: ventilator-associated pneumonia-preventing the inevitable. Clin Infect Dis 2011; 52:115-121.
2. Edgeworth JD. Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. J Antimicrob Chemother 2011; 66 (Suppl 2):ii41-ii47.
3. Jarlier V, Trystram D, Brun-Buisson C, et al. Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med 2010; 170:552-559.
4. Kupfer M, Jatzwauk L, Monecke S, et al. MRSA in a large German University Hospital: male gender is a significant risk factor for MRSA acquisition. GMS Krankenhhyg Interdiszip 2010; 5:Doc11.
5. Hawser SP, Bouchillon SK, Hoban DJ, et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrobial Agents 2011; 37:219-224.
6. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. Jama 2010; 303:2260-2264.
7. Augustin P, Kermarrec N, Muller-Serieys C, et al. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010; 14:R20.
8. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 2010; 14:R113.
9. Seguin P, Fedun Y, Laviolle B, et al. Risk factors for multidrug-resistant bacteria in patients with postoperative peritonitis requiring intensive care. J Antimicrob Chemother 2010; 65:342-346.
10. Aumeran C, Poincloux L, Souweine B, et al. Multidrug-resistant Klebsiella pneumoniae outbreak after endoscopic retrograde cholangiopancreatography. Endoscopy 2010; 42:895-899.
11. Dumpis U, Iversen A, Balode A, et al. Outbreak of CTX-M-15-producing Klebsiella pneumoniae of sequence type 199 in a Latvian teaching hospital. Apmis 2010; 118:713-716.
12. Nielsen JB, Skov MN, Jorgensen RL, et al. Identification of CTX-M15-, SHV- 28-producing Klebsiella pneumoniae ST15 as an epidemic clone in the Copenhagen area using a semi-automated Rep-PCR typing assay. Eur J Clin Microbiol Infect Dis 2011; 30:773-778.
13. Ruiz E, Rojo-Bezares B, Saenz Y, et al. Outbreak caused by a multiresistant Klebsiella pneumoniae strain of new sequence type ST341 carrying new genetic environments of aac(6)-Ib-cr and qnrS1 genes in a neonatal intensive care unit in Spain. Int J Med Microbiol 2010; 300:464-469.
14. Vranic-Ladavac M, Bosnjak Z, Beader N, et al. Clonal spread of CTX-M-15- producing Klebsiella pneumoniae in a Croatian hospital. J Med Microbiol 2010; 59 (Pt 9):1069-1078.
15. Diaz MA, Hernandez-Bello JR, Rodriguez-Bano J, et al. Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol 2010; 48:2840-2845.
16. Smet A, Martel A, Persoons D, et al. Characterization of extended-spectrum beta-lactamases produced by Escherichia coli isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections. Microb Drug Resist 2010; 16:129-134.
17. European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2010. Stockholm: ECDC; 2010.
18. Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-careassociated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11:30-38.
19. Malacarne P, Boccalatte D, Acquarolo A, et al. Epidemiology of nosocomial infection in 125 Italian intensive care units. Minerva Anestesiol 2010; 76:13-23.
20. Schweickert B, Geffers C, Farragher T, et al. The MRSA-import in ICUs is an important predictor for the occurrence of nosocomial MRSA cases. Clin Microbiol Infect 2011; 17:901-906.
21. Rubio-Terres C, Garau J, Grau S, Martinez-Martinez L. Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study. Clin Microbiol Infect 2010; 16:722-728.
22. Ott E, Bange FC, Reichardt C, et al. Costs of nosocomial pneumonia caused by meticillin-resistant Staphylococcus aureus. J Hosp Infect 2010; 76:300-303.
23. Hansen S, Schwab F, Asensio A, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: which infection control measures are taken? Infection 2010; 38:159-164.
24. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-1347. (Pubitemid 36384101)
25. Gould IM. VRSA-doomsday superbug or damp squib? Lancet Infect Dis 2010; 10:816-818.
26. Perichon B, Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53:4580-4587.
27. Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011; 27:163-205.
28. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010; 50:821-825.
29. Soderblom T, Aspevall O, Erntell M, et al. Alarming spread of vancomycin resistant enterococci inSweden since 2007. Euro Surveill 2010; 15:pii:19620.
30. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. Jama 2009; 302:2323-2329.
31. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1-14.
32. Woodford N, Turton JF, Livermore DM. Multiresistant gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35:736-755.
33. Livermore DM, Hill RL, Thomson H, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 2010; 35:19-24.
34. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597-602.
35. Rasheed JK, Biddle JW, Anderson KF, et al. Detection of the Klebsiella pneumoniae carbapenemase type 2 Carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K. oxytoca carrying a common plasmid. J Clin Microbiol 2008; 46:2066-2069. (Pubitemid 351831844)
36. Sidjabat HE, Silveira FP, Potoski BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009; 49:1736-1738.
37. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-1161. (Pubitemid 32230996)
38. Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15:pii:19711.
39. Sidjabat HE, Paterson DL, Qureshi ZA, et al. Clinical features and molecular epidemiology of CMY-type beta-lactamase-producing Escherichia coli. Clin Infect Dis 2009; 48:739-744.
40. Greek System for the Surveillance of Antimicrobial Resistance. http:// www.mednet.gr/whonet. [Accessed June 2011].
41. Cuzon G, Naas T, Demachy MC, Nordmann P. Plasmid-mediated carbapenem- hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother 2008; 52:796-797. (Pubitemid 351170870)
42. Tsakris A, Kristo I, Poulou A, et al. First occurrence of KPC-2-possessing Klebsiella pneumoniae in a Greek hospital and recommendation for detection with boronic acid disc tests. J Antimicrob Chemother 2008; 62:1257-1260.
43. Giakoupi P, Maltezou H, Polemis M, et al. KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 2009; 14:pii:19218.
44. Gaibani P, Ambretti S, Berlingeri A, et al. Rapid increase of carbapenemaseproducing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March to 30 September 2010. Euro Surveill 2011; 16:pii:19800.
45. Kassis-Chikhani N, Decre D, Ichai P, et al. Outbreak of Klebsiella pneumoniae producing KPC-2 and SHV-12 in a French hospital. J Antimicrob Chemother 2010; 65:1539-1540.
46. Mammina C, Palma DM, Bonura C, et al. Outbreak of infection with Klebsiella pneumoniae sequence type 258 producing Klebsiella pneumoniae Carbapenemase in an intensive care unit in Italy. J Clin Microbiol 2010; 48:1506-1507.
47. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenemhydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423-4424. (Pubitemid 41401006)
48. Petrella S, Ziental-Gelus N, Mayer C, et al. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A betalactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother 2008; 52:3725-3736.
49. Samuelsen O, Buaro L, Toleman MA, et al. The first metallo-beta-lactamase identified in norway is associated with a TniC-like transposon in a Pseudomonas aeruginosa isolate of sequence type 233 imported from Ghana. Antimicrob Agents Chemother 2009; 53:331-332.
50. Tegmark Wisell K, Haeggman S, Gezelius L, et al. Identification of Klebsiella pneumoniae carbapenemase in Sweden. Euro Surveill 2007; 12:E0712203.
51. Babouee B, Widmer AF, Dubuis O, et al. Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009- 10. Euro Surveill 2011; 16:pii:19817.
52. Dortet L, Radu I, Gautier V, et al. Intercontinental travels of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1. J Antimicrob Chemother 2008; 61:455-457.
53. Cuzon G, Naas T, Bogaerts P, et al. Plasmid-encoded carbapenem- hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium. Antimicrob Agents Chemother 2008; 52:3463-3464.
54. Leverstein-van Hall MA, Stuart JC, Voets GM, et al. Carbapenem-resistant Klebsiella pneumoniae following foreign travel. Ned Tijdschr Geneeskd 2010; 154:A2013.
55. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64 (Suppl 1):i3-10.
56. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-betalactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046-5054.
57. Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-beta-lactamase. Clin Infect Dis 2011; 52:481-484.
58. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355-362.
59. Struelens MJ, Monnet DL, Magiorakos AP, et al. New Delhi metallo-betalactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 2010; 15:pii:19716.
60. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36 (Suppl 3):S8-14.
61. Bogaerts P, Bouchahrouf W, de Castro RR, et al. Emergence of NDM-1- producing Enterobacteriaceae in Belgium. Antimicrob Agents Chemother 2011; 55:3036-3038.
62. Deshpande P, Shetty A, Kapadia F, et al. New Delhi metallo 1: have carbapenems met their doom? Clin Infect Dis 2010; 51:1222.
63. Hammerum AM, Toleman MA, Hansen F, et al. Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis 2010; 10:829-830.
64. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66:657-663.
65. Wilson AP, Smyth D, Moore G, et al. The impact of enhanced cleaning within the intensive care unit on contamination of the near-patient environment with hospital pathogens: a randomized crossover study in critical care units in two hospitals. Crit Care Med 2011; 39:651-658.
66. Kypraios T, ONeill PD, Huang SS, et al. Assessing the role of undetected colonization and isolation precautions in reducing methicillin-resistant Staphylococcus aureus transmission in intensive care units. BMC Infect Dis 2010; 10:29.
67. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-474.
68. Meyer E, Schwab F, Pollitt A, et al. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. Infection 2010; 38:19-24.
69. Nijssen S, Fluit A, van de Vijver D, et al. Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gramnegative bacteria. Intensive Care Med 2010; 36:512-519.
70. Raineri E, Crema L, Dal Zoppo S, et al. Rotation of antimicrobial therapy in the intensive care unit: impact on incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2010; 29:1015-1024.
71. Buehlmann M, Bruderer T, Frei R, Widmer AF. Effectiveness of a new decolonisation regimen for eradication of extended-spectrum beta-lactamase- producing Enterobacteriaceae. J Hosp Infect 2011; 77:113-117.
72. Bloos F, Marshall JC, Dellinger RP, et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care 2011; 15:R88.
73. Giamarellou H. Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010; 36 (Suppl 2):S50-S54.
74. Kopterides P, Siempos, II, Tsangaris I, et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and metaanalysis of randomized controlled trials. Crit Care Med 2010; 38:2229-2241.
75. Cohen Stuart J, Dierikx C, Al Naiemi N, et al. Rapid detection of TEM, SHV and CTX-M extended-spectrum beta-lactamases in Enterobacteriaceae using ligation-mediated amplification with microarray analysis. J Antimicrob Chemother 2010; 65:1377-1381.
76. Huskins WC, Huckabee CM, OGrady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011; 364:1407-1418.
77. Derde L, Dautzenberg M, van Duijn P, et al. editors. Colonisation and transmission of resistant bacteria in 13 European intensive care units. 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27th International Congress of Chemotherapy (ICC); 2011 May 7 to May 10. Milan. Clin Microbiol Infect 2011; 17(Suppl S4):58.
78. de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360:20-31.
79. de Smet AM, Kluytmans JA, Blok HE, et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered grouprandomised, crossover study. Lancet Infect Dis 2011; 11:372-380.
80. Oostdijk EA, de Smet AM, Kesecioglu J, Bonten MJ. The role of intestinal colonization with gram-negative bacteria as a source for intensive care unitacquired bacteremia. Crit Care Med 2011; 39:961-966.
81. Oostdijk EA, de Smet AM, Blok HE, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010; 181:452-457.
82. Vincent JL, Jacobs F. Effect of selective decontamination on antibiotic resistance. Lancet Infect Dis 2011; 11:337-338.